In addition, the cBioPortal database showed the correlations between EGFR family genetic alterations and overall survival (OS) (p < 0.001), disease-free survival (DFS) (p < 0.001), disease-specific survival (DSS) (p < 0.001), and progression-free survival (PFS) of patients with glioma (p < 0.001) (Fig. 1b, c, d, and e). This evidence concerns the gene EGFR and central nervous system cancer.